FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Kyowa Parkinsons Therapy NDA Resubmitted

FDA accepts for review a Kyowa Hakko Kirin resubmitted NDA for KW-6002 (istradefylline), an investigational selective adenosine A2A receptor antagonis...

Human Drugs

Review Extended on Daiichi Leukemia Drug

FDA extends by three months the review of a Daiichi Sankyo NDA for quizartinib, an investigational FLT3 inhibitor currently under priority review for ...

Federal Register

Hearing on Cannabis Products

Federal Register notice: FDA announces a 5/31 public hearing to obtain scientific data and information about products containing cannabis or cannabis-...

Federal Register

Info Collection on Emergency Use Authorizations

Federal Register notice: FDA seeks comments on an information collection extension related to its Guidance: Emergency Use Authorization of Medical Pro...

Federal Register

Info Collection on Medical Device Accessories

Federal Register notice: FDA seeks comments on an information collection extension related to a guidance entitled Medical Device Accessories.

Biologics

FDA Releases Liveyon FDA-483

FDA releases the FDA-483 issued following a 2018 agency inspection at the Liveyon stem cell distribution facility.

Medical Devices

TherOx SuperSaturated Oxygen Heart Therapy OKd

FDA approves a TherOx PMA for its SuperSaturated Oxygen Therapy that is intended to provide interventional cardiologists with a treatment beyond percu...

Medical Devices

FDA Warns Inova Genomics Lab on Illegal Genetic Tests

FDA warns Inova Genomic Tests about illegally marketing genetic tests intended to predict how consumers will respond to specific drugs.

Human Drugs

FDA Clears Magstim Theta Burst Stimulation

FDA clears a Magstim 510(k) to include intermittent Theta Burst Stimulation as a treatment for Major Depressive Disorder with its Horizon TMS Therapy ...

Looking Back at Gottlieb, Ahead to Sharpless

A Health Affairs article assesses Scott Gottliebs tenure as FDA commissioner in light of three drug policy initiatives and looks ahead to the arrival ...